Document is current
Any future updates will be listed below
-
Authors
Forst, Deborah A.
Podgurski, Alyx F.
Quain, Kit M.
Landay, Sophia L.
Anand, Maya
Kaslow-Zieve, Emilia
Mesa, Michelle M.
Jacobs, Jamie M.
Dietrich, Jorg
Parsons, Michael W.
Horick, Nora
Greer, Joseph A.
Batchelor, Tracy T.
Jackson, Vicki A.
El-Jawahri, Areej
Temel, Jennifer S.
-
Funding
Funding for this research was provided by:
Pappas Center for Neuro-Oncology at Massachusetts General Hospital Cancer Center
Cancer Outcomes Research and Education Program at Massachusetts General Hospital Cancer Center
Dr. El-Jawahri is a Scholar in Clinical Research for the Leukemia and Lymphoma Society
- License Information
-
More Information
Article History
Received: 20 September 2021
Accepted: 11 March 2022
First Online: 30 March 2022
Declarations
:
: This study was approved by The Dana-Farber/Harvard Cancer Center Institutional Review Board and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki.
: All participants provided written informed consent prior to enrollment.
: All authors have approved the final version of this manuscript.
: Dr. Forst: ownership interest in Eli Lilly. Dr. Parsons: consultant fees from Agios Pharmaceuticals and Gamaka Biotechnology, royalties from the American Psychological Association Press. Dr. Greer: research funding from Blue Note Therapeutics, royalties from Humana Press/Springer. Dr. El-Jawahri: consultant fees from AIM Specialty and Blue Note Therapeutics. Dr. Batchelor: Genomicare scientific advisory board. Remaining authors: no disclosures.
